Unicycive Therapeutics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Unicycive Therapeutics Inc 公司

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Unicycive Therapeutics Inc簡介



公司代碼UNCY

公司名稱Unicycive Therapeutics Inc

上市日期Jun 17, 2021

CEOGupta (Shalabh)

員工數量22

證券類型Ordinary Share

年結日Jun 17

公司地址4300 El Camino Real, Suite 210

城市LOS ALTOS

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94022

電話16503840642

網址https://unicycive.com/

公司代碼UNCY

上市日期Jun 17, 2021

CEOGupta (Shalabh)

Unicycive Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Sandeep (Steve) Laumas, M.D.

Independent Director

10.58K

--

Dr. Pramod Gupta, Ph.D.

Executive Vice President - Pharmaceutical and Business Operations

4.18K

--

Dr. Shalabh Gupta, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

--

Mr. John Townsend

Chief Financial Officer

--

Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.

Independent Director

--

Dr. Gaurav Aggarwal, M.D.

Independent Director

--

Mr. Doug Jermasek

Executive Vice President - Corporate Strategy

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Sandeep (Steve) Laumas, M.D.

Independent Director

10.58K

--

Dr. Pramod Gupta, Ph.D.

Executive Vice President - Pharmaceutical and Business Operations

4.18K

--

Dr. Shalabh Gupta, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

--

Mr. John Townsend

Chief Financial Officer

--

Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.

Independent Director

--

Dr. Gaurav Aggarwal, M.D.

Independent Director

--

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 2月19日週四

持股股東

股東類型

持股股東

佔比

Vivo Capital, LLC

8.33%

Millennium Management LLC

5.46%

Octagon Capital Advisors LP

4.65%

Nantahala Capital Management, LLC

4.37%

Great Point Partners, LLC

3.71%

其他

73.49%

持股股東

佔比

Vivo Capital, LLC

8.33%

Millennium Management LLC

5.46%

Octagon Capital Advisors LP

4.65%

Nantahala Capital Management, LLC

4.37%

Great Point Partners, LLC

3.71%

其他

73.49%

股東類型

持股股東

佔比

Hedge Fund

21.10%

Venture Capital

10.70%

Investment Advisor

5.22%

Individual Investor

2.93%

Investment Advisor/Hedge Fund

1.69%

Research Firm

0.67%

Pension Fund

0.36%

其他

57.33%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

65

6.67M

31.03%

-253.32K

2025Q3

61

5.54M

31.38%

-1.91M

2025Q2

62

6.96M

54.51%

-655.75K

2025Q1

65

6.78M

64.49%

-1.12M

2024Q4

62

69.04M

66.51%

+542.97K

2024Q3

57

54.12M

55.45%

+17.71M

2024Q2

48

26.33M

50.66%

-3.75M

2024Q1

46

28.58M

99.15%

+4.37M

2023Q4

45

24.82M

96.62%

+1.55M

2023Q3

47

22.73M

96.91%

+9.25M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Vivo Capital, LLC

1.79M

8.33%

+652.90K

+57.42%

Sep 30, 2025

Octagon Capital Advisors LP

1.00M

4.65%

--

Sep 30, 2025

Nantahala Capital Management, LLC

939.20K

4.37%

--

Sep 30, 2025

Great Point Partners, LLC

796.56K

3.71%

--

Sep 30, 2025

The Vanguard Group, Inc.

658.88K

3.07%

+52.92K

+8.73%

Sep 30, 2025

Gupta (Shalabh K)

597.25K

2.78%

-100.00

-0.02%

Apr 30, 2025

Logos Global Management LP

473.56K

2.2%

+1.00

+0.00%

Sep 30, 2025

Citadel Advisors LLC

41.67K

0.19%

+41.67K

--

Sep 30, 2025

Rosalind Advisors, Inc.

242.49K

1.13%

+242.49K

--

Apr 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

Jun 17, 2025

Merger

10→1

公告日期

除權除息日

類型

比率

Jun 17, 2025

Merger

10→1